Table 2 Comparison of resistance rates of S. aureus strains before and during the COVID-19 pandemic.
Antibiotics | No. (%) of resistant isolates | |||||
|---|---|---|---|---|---|---|
Total (n = 399) | 2018 (n = 97) | 2019 (n = 102) | 2020 (n = 56) | 2021 (n = 78) | 2022 (n = 66) | |
Oxacillin | 92 (23.1) | 18 (18.6) | 20 (19.6) | 20 (35.7) a, b | 19 (24.4) | 15 (22.7) |
Penicillin | 367 (92.0) | 92 (94.8) | 96 (94.1) | 51 (91.1) | 72 (92.3) | 56 (84.8) a |
Erythromycin | 234 (58.6) | 56 (57.7) | 64 (62.7) | 33 (58.9) | 40 (51.3) | 41 (62.1) |
Clindamycin | 205 (51.4) | 46 (47.4) | 60 (58.8) | 29 (51.8) | 35 (44.9) | 35 (53.0) |
Tetracycline | 77 (19.3) | 20 (20.6) | 11 (10.8) | 13 (23.2)b | 18 (23.1)b | 15 (22.7)b |
Trimethoprim-sulfamethoxazole | 46 (11.5) | 15 (15.5) | 14 (13.7) | 7 (12.5) | 6 (7.7) | 4 (6.1) |
Gentamicin | 25 (6.3) | 13 (13.4) | 4 (3.9)a | 3 (5.4) | 3 (3.8)a | 2 (3.0)a |
Ciprofloxacin | 18 (4.5) | 6 (6.2) | 3 (2.9) | 5 (8.9) | 0 (0.0)a | 4 (6.1) |
Levofloxacin | 18 (4.5) | 6 (6.2) | 3 (2.9) | 5 (8.9) | 0 (0.0)a | 4 (6.1) |
Moxifloxacin | 13 (3.3) | 6 (6.2) | 2 (2.0) | 2 (3.6) | 0 (0.0)a | 3 (4.5) |
Rifampicin | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Quinupristin-dalfopristin | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Tigecycline | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Linezolid | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Vancomycin | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
